Can Wellbutrin Be Discontinued at 75 mg?
Yes, Wellbutrin at 75 mg can be discontinued, but it should be tapered first by reducing to the lowest available dose before complete cessation to minimize withdrawal symptoms and prevent potential adverse outcomes.
Tapering Recommendation
The FDA-approved prescribing information for Wellbutrin XL explicitly states that when discontinuing treatment in patients on 300 mg daily, the dose should be decreased to 150 mg once daily prior to discontinuation 1. While the label doesn't specifically address 75 mg doses (which is below standard therapeutic dosing), the principle of gradual dose reduction applies universally to antidepressant discontinuation.
For a patient on 75 mg:
- If using immediate-release formulation: Consider tapering to 37.5 mg daily for 5-7 days before complete discontinuation
- If using sustained-release: The 75 mg SR formulation can be discontinued after ensuring the patient has been stable, though monitoring for withdrawal symptoms is prudent
- Duration of taper: At least 1-2 weeks at the lower dose before stopping completely
Why Tapering Matters
The 2020 Mayo Clinic consensus panel on medication tapering emphasizes that abrupt discontinuation can produce serious withdrawal symptoms, including dysphoria, irritability, insomnia, and a vague sense of being unwell 2. The FDA has issued warnings specifically about serious withdrawal symptoms in patients abruptly discontinued from psychiatric medications.
While bupropion (Wellbutrin) has a different mechanism than SSRIs—working primarily on dopamine and norepinephrine rather than serotonin—withdrawal phenomena can still occur. The evidence shows that:
- Protracted withdrawal symptoms may persist for months after elimination, including dysphoria, irritability, insomnia, and anhedonia 2
- These symptoms must be anticipated, discussed with the patient, and either preempted or treated
- Withdrawal distress should be addressed with adequate clinician time and support
Clinical Context for 75 mg Dosing
The 75 mg dose is below standard therapeutic dosing for depression. Standard dosing guidelines indicate 3:
- Initial dosing: 150 mg once daily
- Therapeutic dosing: 150-300 mg daily
- Maximum: 300 mg daily for sustained-release formulations
If a patient is on 75 mg, this suggests either:
- Dose reduction already in progress (appropriate tapering)
- Subtherapeutic dosing (may indicate treatment failure or intolerance)
- Off-label low-dose use (e.g., for sexual dysfunction from SSRIs 4)
Monitoring During Discontinuation
Watch for:
- Mood changes: Worsening depression, irritability, dysphoria
- Physical symptoms: Headache, fatigue, dizziness
- Sleep disturbances: Insomnia or hypersomnia
- Cognitive changes: Difficulty concentrating, confusion
Special Considerations
Do NOT abruptly discontinue if the patient:
- Has a history of severe depression with multiple relapses
- Is using bupropion for smoking cessation (may lead to relapse)
- Has comorbid anxiety or other psychiatric conditions
- Recently experienced significant life stressors
Neuropsychiatric monitoring is essential, as bupropion carries warnings about depression and suicidal ideation, though the EAGLES trial showed no significant increase in neuropsychiatric events compared to placebo 3.
Common Pitfalls to Avoid
- Assuming low doses don't require tapering: Even subtherapeutic doses can cause withdrawal if stopped abruptly
- Failing to discuss withdrawal symptoms proactively: Patients should know what to expect
- Not having a follow-up plan: Schedule reassessment within 1-2 weeks of complete discontinuation
- Ignoring the reason for discontinuation: If stopping due to side effects, ensure alternative treatment is in place if depression persists